Tagworks Pharmaceuticals, based at the Nijmegen University Medical Center, has developed a new technology that targets tumor delivery of chemotherapeutic drugs in extreme cases. By controlling the “click release†of chemotherapeutic drugs from their carrier bound to the tumor, researchers can activate the release of drugs for treatment in the right place. The company published their latest research on this mouse in Nature Communications.
Antibody drug conjugates (ADCs) are relatively new anti-cancer drugs. It consists of an antibody that binds to a tumor-killing chemotherapeutic drug that can be targeted to recognize and bind to cellular receptors. The antibodies on ADCs are mainly used to bind tumor cell-specific extracellular receptors. The drug is released after the receptor has delivered the entire structure into the cell, and the chemotherapeutic drug then exerts its effect in the cell.
ADCs are now used to treat lymphoma and metastatic breast cancer. "These ADCs work very well," said Marc Robillard of Tagworks Pharmaceuticals. "But for many other cancers, including colorectal and ovarian cancers, these methods do not work. The problem is that there are not many tumor-specific receptors that can automatically capture the drug into the cell, and if the ADCs stay outside the cell, then The drug will not be released."
Therefore, it is critical to ensure that the ADC is still extracellularly releasing drugs. In order to achieve this goal, Tagworks has designed a smart ADCs. This type of ADCs binds to the receptors of cancer cells after it is injected into the body, and after 1-2 days, the cells are rich in ADCs. Robillard said: "Our innovation is that we use the second component, which can be used to 'click and release' chemotherapy drugs from the ADC. The result is a rapid release of a large number of chemotherapeutic drugs that attack the tumor. This method promises to treat a variety of cancer."
The results of this study in mice were published recently. Robillard said: “We studied ovarian cancer and malignant colorectal cancer. We have observed strong anti-cancer effects in both cancers. For comparison, we also used the traditional ADC, but this drug is in two. None of these cancers have any effect.â€
GMP Certificated Immune Globulin Injection Supplier in China
Hepatitis B Immunoglobulin,Hep B Immunoglobulin,Hepatitis B Immunoglobulin Vaccine,Hepatitis Immune Globulin
FOSHAN PHARMA CO., LTD. , https://www.full-pharma.com